Olympus Corporation (TYO:7733)
Japan
· Delayed Price · Currency is JPY 1,850.00
-32.50 (-1.73%)
Sep 29, 2025, 3:30 PM JST
Revenue by Product
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2013 - 2020 |
| Scientific Solutions Division | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Scientific Solutions Division Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Division Revenue (Pre-FY2025 Reporting) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Division Revenue (Pre-FY2025 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 530.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Endoscopic Solutions Division | 636.14B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Endoscopic Solutions Division Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Therapeutic Solutions Division | 360.66B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Therapeutic Solutions Division Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Division Revenue (Post-FY2024 Reporting) | 530.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Gastrointestinal Solutions Division | 674.04B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Surgical & Interventional Solutions Division | 322.76B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 530.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 530.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2013 - 2020 |
| Other | -15.16B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Scientific Solutions Division Operating Profit | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Scientific Solutions Division Operating Profit Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Division Operating Profit (Pre-FY2025 Reporting) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Division Operating Profit (Pre-FY2025 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Eliminations from Division Operating Profit | -39.92B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Eliminations from Division Operating Profit Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | -15.16B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Endoscopic Solutions Division Operating Profit | 141.40B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Endoscopic Solutions Division Operating Profit Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Therapeutic Solutions Division Operating Profit | 61.45B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Therapeutic Solutions Division Operating Profit Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Division Operating Profit (Post-FY2024 Reporting) | -473.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Gastrointestinal Solutions Division Operating Profit | 168.37B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Surgical & Interventional Solutions Division Operating Profit | 14.21B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | -15.16B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2013 - 2020 |
| Other | 530.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | -94.40% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 530.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | -94.40% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Japan | 110.11B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Japan Growth | -6.21% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| North America | 413.81B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| North America Growth | 5.13% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe | 254.62B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe Growth | 2.13% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Countries | 28.84B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Countries Growth | 8.54% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China | 95.72B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China Growth | -12.95% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Asia and Oceania Revenue (Post-FY2019 Reporting) | 93.69B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Asia and Oceania Revenue (Post-FY2019 Reporting) Growth | 7.80% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 530.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | -94.40% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2013 - 2020 |
| Company's Total Revenue Growth Rate After FX Adjustment | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Endoscopic Solutions Division (ESD) Revenue Growth Rate After FX Adjustment | 4.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Therapeutic Solutions Division (TSD) Revenue Growth Rate After FX Adjustment | 3.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| ESD - GI Endoscopy Revenue Growth Rate After FX Adjustment | 3.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| ESD - Surgical Endoscopy Revenue Growth Rate After FX Adjustment | 5.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| ESD - Medical Service Revenue Growth Rate After FX Adjustment | 5.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| TSD - GI EndoTherapy Revenue Growth Rate After FX Adjustment | 2.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| TSD - Urology Revenue Growth Rate After FX Adjustment | 6.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| TSD - Respiratory Revenue Growth Rate After FX Adjustment | 10.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| TSD - Other Therapeutic Areas Revenue Growth Rate After FX Adjustment | -7.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|